Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Objectives: To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC). Data sources: Electronic databases, including...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein
Format: Artigo
Langue:Inglês
Publié: NIHR Journals Library 2010-01-01
Collection:Health Technology Assessment
Sujets:
bevacizumab
sorafenib-tosylate
sunitinib
temsirolimus
renal-cell-carcinoma
systematic-review
economic-evaluation
Accès en ligne:https://doi.org/10.3310/hta14020
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires